• 1
    Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999 [see comments]. CA Cancer J Clin. 1999; 49: 831.
  • 2
    Lynch HT, Watson P, Tinley S, et al. An update on DNA-based BRCA1/BRCA2 genetic counseling in hereditary breast cancer. Cancer Genet Cytogenet. 1999; 109: 918.
  • 3
    Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994; 266: 6671.
  • 4
    Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994; 265: 208890.
  • 5
    Tavtigian SV, Simard J, Rommens J, et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds [see comments]. Nat Genet. 1996; 12: 3337.
  • 6
    Frank TS, Manley SA, Olopade OI, et al. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol. 1998; 16: 241725.
  • 7
    ASCO Subcommittee on Genetic Testing for Cancer Susceptibility. Statement of the American Society of Clinical Oncology. Genetic testing for cancer susceptibility. J Clin Oncol. 1996;14: 17306.
  • 8
    Lerman C, Seay J, Balshem A, Audrain J. Interest in genetic testing among first-degree relatives of breast cancer patients. Am J Med Genet. 1995; 57: 38592.
  • 9
    Durfy SJ, Bowen DJ, McTiernan A, Sporleder J, Burke W. Attitudes and interest in genetic testing for breast and ovarian cancer susceptibility in diverse groups of women in western Washington. Cancer Epidemiol Biomarkers Prev. 1999; 8: 36975.
  • 10
    Lerman C, Daly M, Masny A, Balshem A. Attitudes about genetic testing for breast-ovarian cancer susceptibility. J Clin Oncol. 1994; 12: 84350.
  • 11
    Julian-Reynier C, Eisinger F, Vennin P, et al. Attitudes towards cancer predictive testing and transmission of information to the family. J Med Genet. 1996; 33: 7316.
  • 12
    Loader S, Levenkron JC, Rowley PT. Genetic testing for breast-ovarian cancer susceptibility: a regional trial. Genet Test. 1998; 2: 30513.
  • 13
    Tambor ES, Rimer BK, Strigo TS. Genetic testing for breast cancer susceptibility: awareness and interest among women in the general population. Am J Med Genet. 1997; 68: 439.
  • 14
    Cappelli M, Surh L, Humphreys L, et al. Psychological and social determinants of women's decisions to undergo genetic counseling and testing for breast cancer. Clin Genet. 1999; 55: 41930.
  • 15
    Andrykowski M, Lightner R, Studts J, Munn R. Hereditary cancer risk notification and testing: how interested is the general population? J Clin Oncol. 1997; 15: 213948.
  • 16
    Ulrich C, Kristal A, White E, Hunt J, Durfy S, Potter J. Genetic testing for cancer risk: a population survey on attitudes and intention. Community Genet. 1998; 1: 21322.
  • 17
    Geller G, Doksum T, Bernhardt BA, Metz SA. Participation in breast cancer susceptibility testing protocols: influence of recruitment source, altruism, and family involvement on women's decisions. Cancer Epidemiol Biomarkers Prev. 1999; 8: 37783.
  • 18
    Armstrong K, Calzone K, Stopfer J, Fitzgerald G, Coyne J, Weber B. Factors associated with decisions about clinical BRCA1/2 testing. Cancer Epidemiol Biomarkers Prev. 2000; 9: 12514.
  • 19
    Couch FJ, DeShano ML, Blackwood MA, et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer [see comments]. N Engl J Med. 1997; 336: 140915.
  • 20
    Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet. 1994;343: 6925.
  • 21
    Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews [see comments]. N Engl J Med. 1997; 336: 14018.
  • 22
    Burke W, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium [see comments]. JAMA. 1997;277: 9971003.
  • 23
    Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study [see comments]. J Natl Cancer Inst. 1998; 90: 137188.
  • 24
    Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial [see comments]. Lancet. 1998; 352: 98101.
  • 25
    Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study [see comments]. Lancet. 1998;352: 937.
  • 26
    Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer [see comments]. N Engl J Med. 1999; 340: 7784.
  • 27
    Schrag D, Kuntz KM, Garber JE, Weeks JC. Decision analysis—effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations [see comments] [published erratum appears in N Engl J Med. 1997;337:434]. N Engl J Med. 1997;336: 146571.
  • 28
    Piver MS, Jishi MF, Tsukada Y, Nava G. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer. 1993;71: 27515.
  • 29
    Tonin P, Weber B, Offit K, et al. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families [see comments]. Nat Med. 1996; 2: 117983.
  • 30
    Chaliki H, Loader S, Levenkron JC, Logan-Young W, Hall WJ, Rowley PT. Women's receptivity to testing for a genetic susceptibility to breast cancer. Am J Public Health. 1995; 85: 11335.
  • 31
    Richards CS, Ward PA, Roa BB, et al. Screening for 185delAG in the Ashkenazim. Am J Hum Genet. 1997; 60: 108598.
  • 32
    Meijers-Heijboer EJ, Verhoog LC, Brekelmans CT, et al. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet. 2000; 355: 201520.
  • 33
    Martin AM, Blackwood MA, Antin-Ozerkis D, et al. Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic. J Clin Oncol. 2001; 19: 224753.
  • 34
    Lerman C, Narod S, Schulman K, et al. BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes [see comments]. JAMA. 1996;275: 188592.
  • 35
    Matloff ET, Shappell H, Brierley K, Bernhardt BA, McKinnon W, Peshkin BN. What would you do? Specialists' perspectives on cancer genetic testing, prophylactic surgery, and insurance discrimination. J Clin Oncol. 2000;18: 248492.
  • 36
    Gilpin CA, Carson N, Hunter AG. A preliminary validation of a family history assessment form to select women at risk for breast or ovarian cancer for referral to a genetics center. Clin Genet. 2000; 58: 299308.
  • 37
    Meijers-Heijboer H, van Geel B, van Putten WL,et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001; 345: 15964.
  • 38
    Rebbeck TR, Levin AM, Eisen A, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst. 1999; 91: 14759.
  • 39
    Narod SA, Brunet JS, Ghadirian P, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case–control study. Hereditary Breast Cancer Clinical Study Group. Lancet. 2000;356: 187681.
  • 40
    King MC, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA. 2001; 286: 22516.